Skip to Content
CancersCancers
  • Review
  • Open Access

4 February 2026

21 Pages

Advances and Emerging Techniques in Transarterial Chemoembolization for Hepatocellular Carcinoma

,
,
,
and
1
Division of Interventional Radiology, Department of Radiology, The Ohio State University Wexner Medical Center, 395 W 12th Ave, 4th Floor Faculty Office Tower, Columbus, OH 43210, USA
2
College of Medicine, The Ohio State University, 1645 Neil Avenue, Columbus, OH 43210, USA
3
College of Medicine, Northeast Ohio Medical University, 4209 St. Rt. 44, Rootstown, OH 44272, USA
*
Author to whom correspondence should be addressed.

Simple Summary

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is often asymptomatic until late-stage disease when treatment options are limited. Surgical resection and transplantation remain the gold standard for early-stage disease. However, these are not options for those presenting in later stages or those with prohibitive surgical risk. Transarterial chemoembolization (TACE) is a first-line treatment recommendation for patients with intermediate-stage disease and advances are looking to expand treatment indications and improve outcomes. Enhanced TACE techniques with new materials and procedural methods have already shown promising results. Novel TACE combination therapies with radiation, ablation, and immunotherapy are looking to advance this area further. This review will highlight advances in TACE, summarize new prognostic models and discuss future directions with HCC treatment.

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

HCC is the most common primary liver cancer and the third leading cause of cancer-related death overall [...]

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.